Lomex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lomex

What is Lomex?

Lomex is a pharmaceutical treatment categorized as an antifungal medication. It is primarily used to address various fungal infections affecting the skin and mucous membranes. The active therapeutic component in Lomex belongs to the imidazole class of antifungals, which are known for their ability to manage the growth of yeast and fungi.

Mechanism of Action

Lomex works by interfering with the cellular structure of the infecting fungi. It specifically inhibits the synthesis of ergosterol, a vital component of the fungal cell membrane. By disrupting the integrity of this membrane, the medication prevents the fungi from multiplying and allows the body's natural defenses to clear the infection.

Clinical Applications

Lomex is commonly utilized for the following conditions:

  • Vaginal Candidiasis: Treatment of yeast infections caused by Candida species.
  • Dermatomycosis: Management of fungal skin infections, including ringworm, athlete's foot, and pityriasis versicolor.
  • Mucosal Infections: Addressing fungal overgrowth in other sensitive areas of the body.

Available Forms

To accommodate different types of infections, Lomex is produced in several formulations, including:

  • Topical Creams: For application on the skin.
  • Vaginal Ovules or Capsules: For localized internal treatment.
  • Sprays or Powders: For use on larger or high-moisture skin areas.

Lomex is designed to provide targeted action at the site of infection with minimal systemic absorption into the bloodstream.

What side effects are possible with Lomex?

Possible Side Effects and Safety Information

The safety profile of Lomex (Omeprazole) is officially documented by regulatory agencies and features adverse reactions categorized by frequency and the body system affected. These classifications establish the medicine’s risk characteristics in a neutral, non-advisory manner.

Frequency and System-Organ Classifications

Adverse reactions are formally grouped into categories based on their reported incidence.

Classification Examples of Officially Listed Effects
Common Headache, abdominal pain, diarrhea, flatulence, constipation, nausea/vomiting.
Uncommon Dizziness, insomnia, paresthesia, skin rash, pruritus, malaise.

Clinically Significant Adverse Reactions

The official label lists rare to very rare events considered clinically serious. These include severe allergic reactions, such as anaphylaxis and angioedema, as well as severe cutaneous adverse reactions like Stevens-Johnson Syndrome. Rare blood disorders (e.g., agranulocytosis) and hepatic failure are also documented safety concerns.

Duration-Related Safety Patterns

Regulatory documents explicitly link certain risks to the duration of exposure. Long-term use (typically one year or more) is associated with an increased risk of bone fractures of the hip, wrist, or spine. Additionally, prolonged use is associated with the risk of Clostridium difficile-associated diarrhea and the development of benign gastric polyps.

Safety Restrictions and Contraindications

Lomex is contraindicated in individuals with a known hypersensitivity to the active substance, other substituted benzimidazoles, or any component of the formulation. Regulatory warnings also note a safety risk related to concomitant use with certain other medicines, such as Clopidogrel.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action for Lomex

The official regulatory documentation identifies specific manifestations reported following Omeprazole overdosage. These include effects on the Central Nervous System such as confusion, drowsiness, and headache. Other documented signs involve autonomic and ocular effects like blurred vision, flushing, increased sweating, and dryness of the mouth. Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and abdominal pain have also been documented in cases of high-dose exposure.

When to Seek Immediate Medical Help

Urgent medical attention is mandated when overdosage is suspected, including contacting a Poison Control Center or emergency services. While large single oral doses are reported not to result in severe symptoms, immediate emergency action is required if the individual displays severe clinical signs including trouble breathing, seizure, or collapse (inability to be awakened).

Official Management and Treatment Constraints

The regulatory profile states that no specific antidote is known for Omeprazole overdose. Consequently, the management approach is strictly symptomatic and supportive treatment. This includes the monitoring of vital signs and the potential consideration of measures to reduce absorption, such as gastric lavage or the administration of activated charcoal, particularly if ingestion was recent.

Therapeutic Uses of Lomex

Omeprazole (Lomex) is commonly used for managing conditions that involve symptoms related to heightened physiological activity (acid production), which provides supportive therapeutic benefit across key upper gastrointestinal domains.

Main Uses and Therapeutic Benefits

This medication is applied in addressing conditions marked by recurrent, severe symptoms like frequent heartburn, bothersome acid regurgitation, and chronic indigestion. It is commonly used for managing conditions characterized by physical injury to the digestive lining, including duodenal and gastric ulcers and erosive esophagitis. It is also relevant in specialized clinical situations like Zollinger-Ellison Syndrome (ZES) and in combination with other agents to help treat the bacterium H. pylori.

Lomex may support the healing of these lesions and helps protect the stomach lining against damage when patients must take ulcer-causing medications like NSAIDs. It contributes to improved comfort during periods of heightened symptoms and offers symptomatic relief that supports the patient in maintaining functional stability and helps address symptoms that interfere with daily comfort.

“The primary benefit may be the support for control over acid output, which assists patients in coping more steadily with symptom fluctuations that disrupt routine activities.”


Quick Fact: Managing Chronic Acid Symptoms

Lomex may be applied in contexts where continuous support for acid reduction is relevant for managing documented tissue damage, such as ulcers, and for managing the recurrent, disruptive nature of GERD symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Lomex? — Official Regulatory Information

The use of Lomex (Omeprazole) is strictly defined by official regulatory criteria, outlining populations who are absolutely contraindicated and those who require conditional use.


Eligibility Scope

  • Populations for whom use is contraindicated: Patients with a known history of hypersensitivity to omeprazole or any substituted benzimidazole compound. Use is also prohibited for patients receiving concomitant medication with nelfinavir or rilpivirine-containing products.

  • Age-related eligibility rules: Adults are approved for all labeled uses. Pediatric use is established for children one month of age and older for certain conditions; however, safety and effectiveness are not established in infants younger than one month.

  • Condition-specific eligibility rules: Patients with impaired hepatic function require special caution and may necessitate a conditional adjustment. Patients with rare hereditary disorders like Lapp Lactase deficiency are generally not recommended to use the medicine.

  • Pregnancy and lactation eligibility status: Use is conditional during pregnancy, reserved for when the potential benefit justifies the potential risk. Excretion into breast milk is at very low levels, though some regulatory bodies advise caution.


Connection to the overall eligibility profile: Official regulatory documents define eligibility through absolute prohibitions and mandatory conditional use rules. These criteria govern the legal scope of use and ensure the medicine is only prescribed where its use has been officially established or deemed permissible under specific patient conditions.

What should I know about interactions with other medicines?

Lomex (omeprazole) is associated with several officially documented interactions that are classified based on regulatory significance, primarily stemming from its effect on gastric pH and its role as an inhibitor of the CYP2C19 enzyme.


Interaction Classification Documented Restrictions & Consequences
Contraindicated Combinations Co-administration is formally prohibited with Nelfinavir and Rilpivirine-containing products, as omeprazole causes a significant, unacceptable reduction in the plasma concentrations of these antivirals.
Exposure-Altering Interactions Omeprazole's CYP2C19 inhibition reduces the formation of the active metabolite of Clopidogrel. This inhibition also increases the exposure of drugs like Diazepam, Phenytoin, and Cilostazol by decreasing their clearance.

Other Documented Interaction Notes:

  • pH-Dependent Absorption: Omeprazole-induced gastric pH elevation decreases the absorption and therapeutic concentration of medicines requiring an acidic environment, such as Ketoconazole, Itraconazole, and Erlotinib. Conversely, it can increase the exposure of Digoxin.
  • Inducers and Inhibitors: Strong CYP inducers like Rifampin and the herbal product St. John’s Wort are documented to decrease omeprazole plasma levels. Conversely, the CYP inhibitor Voriconazole significantly increases omeprazole exposure.
  • Specific Restrictions: Co-administration with Atazanavir is restricted and should only occur if Atazanavir is also combined with Ritonavir, under specified dosing conditions. Caution is noted for its use with Methotrexate and Mycophenolate Mofetil due to the potential for altered exposures, respectively.

Mechanism of Action

The drug acts primarily through peripheral modulation of the digestive tract. Its mechanism begins with the selective binding and activation (agonism) of mu-opioid receptors located on the nerve cells (myenteric plexus) within the intestinal wall. This binding inhibits the release of excitatory neurotransmitters, such as acetylcholine.

This biochemical action reduces the speed and force of propulsive peristalsis, the muscle contractions that move intestinal contents forward, consequently slowing transit time. The reduced transit time facilitates the inhibition of excessive fluid secretion and promotes the reabsorption of water and essential salts across the intestinal lining. This combined mechanistic effect alters fluid distribution within the bowel, resulting in intestinal contents with a reduced water-to-solid ratio.

Dosage and Administration Information

How to Use Lomex: Official Administration Guidelines

Lomex (Omeprazole) is primarily administered via the oral route as a delayed-release capsule containing enteric-coated pellets. This specific pharmaceutical design is critical, as it protects the active substance from degradation by stomach acid. The medicine is also approved for intravenous (IV) use when the oral route is not appropriate, such as in certain hospital settings.

Administration and Timing Principles

Oral administration of Lomex is consistently directed to occur before a meal, typically once daily, to optimize its intended action. The delayed-release capsule must be swallowed whole with water and should not be crushed, chewed, or opened, as altering the capsule compromises the essential enteric coating.

Standard Dosing Regimens and Frequency

Standard adult dosing for conditions like duodenal ulcer or erosive esophagitis typically involves 20 mg or 40 mg taken once daily for short courses, usually four to eight weeks. For specialized uses, such as managing pathological hypersecretory conditions, the dose may be significantly higher, starting at 60 mg once daily. When the total daily dose exceeds 80 mg, official guidelines mandate that the total amount be split and administered in divided doses (e.g., twice daily) to maintain effective acid control.

Population and Procedural Rules

Official labeling addresses regimen adjustments for certain populations. For patients with hepatic impairment (reduced liver function), a lower daily dose, such as 10 mg to 20 mg, may be considered appropriate. In general, the intravenous form is prepared by diluting the powder in a specific solution and must be given as a slow infusion over 20 to 30 minutes. If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped to maintain the proper schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for Lomex (Omeprazole)

This section provides a factual overview of the research and studies conducted for Lomex, focusing on the types of evidence that exist and what those studies were designed to measure, according to authoritative scientific and regulatory sources. This information is purely descriptive and should not be used for clinical decision-making.

Evidence for Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis

Research exploring how symptoms change over time in GERD and studies examining the healing of lesions in Erosive Esophagitis primarily consist of Randomized Controlled Trials (RCTs) and systematic reviews. Short-term RCTs described patterns related to the healing of the esophageal lining over periods typically ranging from four to eight weeks. Additionally, studies monitored measurements of symptom intensity or variability in the observed populations.

In intermediate-term studies exploring maintenance, research examined the proportion of participants who retained endoscopic evidence of a healed state for up to one year, following an acute treatment phase. What remains uncertain is the full characterization of long-term outcomes for patients beyond one year of use. The original pivotal studies primarily focused on short-term outcomes.

Evidence for Healing Duodenal and Gastric Ulcers

The evidence base for Duodenal and Gastric Ulcers was evaluated in numerous RCTs focused on outcomes related to ulcer healing and the prevention of recurrence. These studies explored outcomes linked to inflammatory or irritative states, reporting how symptoms related to physical discomfort evolved in the observed populations during the short-term healing phase (typically 4–8 weeks).

Comparative evidence indicates that Omeprazole was studied for outcomes related to healing and recurrence against other classes of acid reducers (H2-receptor antagonists) in specific trials. The follow-up durations for many of the acute healing trials were limited to the short-term, meaning the evidence related to the longer-term stability of the healed state is a subject where data are still emerging.

Research in H. pylori Eradication and NSAID Injury Prevention

For H. pylori Eradication, Lomex was studied for use as a necessary part of a multi-drug regimen. These RCTs measured the bacterial clearance rate confirmed by lab tests. Findings indicate that the success rate was associated with the specific combination of antibiotics chosen and local patterns of bacterial resistance.

For the Prevention of NSAID-Associated Gastric Injury, research examined the use of Omeprazole in RCTs of high-risk adults who required chronic NSAID treatment. These studies monitored the endoscopic incidence of new ulcers or erosions. Data for protective effects in the lower digestive tract are more limited.

Long-Term Evidence and Maintenance Studies

Research has explored the maintenance of the healed esophageal lining in participants following an initial acute treatment phase. For patients with rare, severe conditions, such as Zollinger-Ellison Syndrome (ZES), observational cohorts have provided extended follow-up data describing long-term objective control of acid output. However, the certainty regarding very long-term effects (many years) on various health outcomes remains low, and continuous research is ongoing.

Key Studies & References

  1. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management - NICE Guideline CG184
  2. Omeprazole - StatPearls - NCBI Bookshelf (NIH)
  3. A Comprehensive Review on Omeprazole: Pharmacological Effects and Its Adverse Effects (Focusing on long-term data)

Frequently Asked Questions (FAQ)

Common questions about Lomex (FAQ)


Q: Can Lomex make you feel tired or dizzy?

Official regulatory documents state that both dizziness and fatigue (tiredness) are reported as adverse effects of Lomex. These are classifications used by regulatory agencies to describe patterns observed in studies and post-marketing reports.


Q: Are there any long-term health risks from taking Lomex?

Official prescribing information indicates that prolonged use, typically defined as one year or more, is associated with certain documented risks. These risks include an increased risk of bone fractures, particularly of the hip, wrist, or spine. Additionally, long-term use has been noted in connection with Clostridium difficile-associated diarrhea and the development of atrophic gastritis.


Q: Is it safe to take Lomex if I also take a vitamin supplement?

Official drug interaction documents do not typically list a direct interaction with general vitamins. However, regulatory sources note that prolonged use of medicines in this class has been associated with magnesium imbalance and potential effects on bone health.


Q: Can I have coffee or alcohol while I am using Lomex?

Regulatory sources regarding drug-to-drug interactions do not list a direct chemical interaction between Lomex and alcohol or general dietary components like coffee. However, certain substances may be known to increase acid production.


Q: Do I need to change my diet while taking Lomex?

Official information regarding the administration of Lomex indicates there are no specific foods that directly interact with or need to be avoided when taking the medicine. The official product information notes that Lomex is typically administered before a meal.


Q: Is Lomex safe to use if I have a history of heart problems?

Regulatory documents specifically warn against the co-administration of Lomex with the antiplatelet drug Clopidogrel. This is because Lomex may inhibit the activity of Clopidogrel. The information describes the importance of considering concurrent antiplatelet medication when reviewing eligibility.


Q: Does Lomex interfere with birth control or other hormonal medicines?

The official prescribing label does not list a specific interaction between Lomex and oral contraceptives. However, some post-marketing data has suggested a potential association between PPIs and the onset of certain sexual dysfunctions or hormonal changes.


Q: Are the side effects of Lomex permanent?

Official pharmacological information addresses the reversibility of certain physiological changes associated with acid suppression, such as changes in the stomach lining. These changes are described as appearing reversible upon cessation of the medication.


Q: What kind of monitoring is needed while taking Lomex?

For patients receiving prolonged treatment, official documents suggest that monitoring of magnesium levels may be considered due to the potential for hypomagnesemia (low magnesium). Monitoring may also be considered when Lomex is used alongside certain other medications that may affect electrolyte levels.


Q: How long does Lomex typically stay in the body after the last dose?

Pharmacological studies indicate that the drug itself is rapidly eliminated from the blood plasma, with a typical half-life of about one hour. However, the medicine works by irreversibly binding to the acid pumps, meaning the therapeutic effect of reduced acid secretion lasts significantly longer.


Q: Why is Lomex given for different conditions?

The medicine's specific action is to inhibit the final step of acid secretion, regardless of the chemical or physiological trigger. Because it blocks the proton pump, which is the final acid-producing mechanism, its mechanism allows it to be indicated for various conditions related to excess acid.


Q: How quickly should I expect Lomex to start working?

Official information indicates that the onset of the acid-reducing effect typically begins within one hour of administration, reaching its maximum effect within two hours. The full inhibitory effect is generally reached after four days of consistent daily dosing.


Q: Is it normal to feel no different after starting Lomex?

Research cited by regulatory bodies acknowledges that some patients may continue to experience symptoms despite starting treatment with a proton pump inhibitor like Lomex. Research indicates that if symptoms persist, it is a pattern that may warrant further review.


Q: What evidence supports the use of Lomex for its primary purpose?

Studies indicate that once-daily oral dosing provides for rapid and effective inhibition of gastric acid secretion. This is quantified by a mean decrease of at least 80% in 24-hour intragastric acidity in most patients, which is the key mechanism supporting its primary uses.


Q: Has Lomex been studied in children or adolescents?

Yes, the medicine has been investigated in controlled and non-controlled studies in pediatric patients. This research covers ages one month and older for conditions such as severe reflux esophagitis and gastroesophageal reflux disease (GERD).


Q: Why is Lomex available as different forms (e.g., tablet, liquid)?

Lomex is typically available as delayed-release capsules for standard oral use. It is also available in forms like oral suspension or intravenous (IV) solutions to accommodate patients who are unable to swallow an intact capsule or who require non-oral therapy, such as in a hospital setting.


Q: Are there generic versions of Lomex available?

Yes, the active ingredient in Lomex is Omeprazole, which is the generic name for the medicine. Both prescription and over-the-counter formulations of omeprazole are widely available.


Q: What is the risk of stopping Lomex suddenly?

Stopping the medication may be associated with the potential risk of rebound hypersecretion. This is a physiological response where the body attempts to restore acid secretion, which could potentially lead to a quick return or worsening of acid-related symptoms.


Q: Can Lomex affect my sleep schedule?

Official adverse reaction lists include insomnia (difficulty sleeping) as an uncommon side effect of the medicine. This is a pattern observed in a small percentage of people who used the medication in clinical trials.


Q: What is the scientific basis for the claims made about Lomex?

The scientific basis is its function as a Proton Pump Inhibitor (PPI). This means it acts as a specific, long-lasting inhibitor of the H^+, K^+-ATPase enzyme (the acid pump) in the stomach lining, effectively blocking the production of gastric acid.


Q: Can men and women use Lomex with the same general expectations?

While most therapeutic expectations apply to both sexes, some post-marketing data has suggested a potential association between PPIs and the onset of sexual dysfunctions. These observed effects in both male and female individuals may represent specific gender concerns addressed in safety data.


Q: Why do people sometimes need to use Lomex for a long time?

Regulatory documents indicate that long-term use is typically reserved for conditions that require sustained acid suppression. Examples include certain chronic, severe reflux diseases or for the prevention of ulcers in patients requiring long-term treatment with NSAID medications.

How should Lomex be stored and disposed of?

How to Store and Dispose of Lomex (Omeprazole)

Storage and Protection Requirements

Lomex (Omeprazole) capsules must be stored strictly according to regulatory standards to maintain the stability of the active ingredient and the integrity of the enteric coating. Store the product at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), ensuring the temperature does not exceed 30 C. The medication must be kept in its original container, tightly closed, and protected from both light and moisture. To ensure safety, store the product out of the sight and reach of children.

Disposal Instructions

Unused or expired Lomex should not be disposed of in wastewater (flushed down the toilet or sink) or in normal household trash. The official regulatory guidance recommends returning the unused medication to a pharmacy or using a community drug take-back program. Disposal must comply with all local environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lomex found in:

A-Z Index: